RFA-DK-22-511: Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to the applicants described in the notice. Applications closed on June 7, 2023.
From the official notice on Grants.gov, last changed February 7, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU54
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$833,334
- Typical project length10.5 years
- U54, Specialized Center Cooperative Agreement. A research center with several projects and shared cores, with substantial NIH involvement. Other open U54 notices.
Projects funded under RFA-DK-22-511 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-22-511 in the NIH Guide.
Key dates
| Posted | February 7, 2023 |
|---|---|
| Deadline | June 7, 2023 |
| Archived by Grants.gov | July 13, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites applications from the two previously funded Rare and Atypical DIAbetes NeTwork (RADIANT) research centers to further study rare and atypical forms of diabetes mellitus. These centers will continue to identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of diabetes mellitus in the general population. RADIANT will also continue to develop community resources to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. During this grant cycle, RADIANT will establish precision diagnoses for new Mendelian forms of diabetes by enrolling family members of previously enrolled participants with a family history suggestive of a Mendelian form of diabetes to aid in identifying potential causal variants. In addition, in vitro and basic studies leveraging induced pleuripotent stem cells (iPSCs) differentiated into tissues of interest will be used to establish pathogenicity of potential causal variants.
Funded under RFA-DK-22-511 so far
NIH funded 2 projects under RFA-DK-22-511 in fiscal 2024 to 2026, at 2 institutions. The median yearly award was $833,334.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Administrative Core | University of Chicago | 2026 | $337,618 |
| RARE and Atypical Diabetes Network(RADIANT) | Baylor College of Medicine | 2026 | $982,544 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-22-511 still open?
No. It closed on June 7, 2023.
Who can apply for Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)?
Closed June 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DK-22-511?
NIH RePORTER lists 2 projects funded under RFA-DK-22-511 in fiscal 2024 to 2026, at 2 institutions. The most were at University of Chicago, Baylor College of Medicine.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- Health and Extreme Weather Solutions-Focused Research Hubs (U54 - Clinical Trial Optional)
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
- Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed)